The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
After Amgen’s KRAS confirmatory trial results were rejected by the FDA as uninterpretable, Bristol Myers Squibb has provided ...
(Reuters) - The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris. Amgen's drug will be marketed ...
The approval comes with a black-box warning about the risk of serious infections caused by a bacteria called neisseria meningitidis. Amgen's drug will be marketed under the name Bkemv. Biosimilars ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi for mantel cell lymphoma. The agency has delay a decision on Dupixent in ...
The Food and Drug Administration last week approved an innovative new treatment for patients with a form of lung cancer. It ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to Regeneron Pharmaceuticals' blockbuster ...
(Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder ... and atypical hemolytic uremic syndrome - can cause ...
Food and Drug Administration. FDA approves new treatment for uncomplicated urinary tract infections. Utility Therapeutics. Existing first-line treatments have declining utility in combating UTI ...